I'll let Ken share how he overcome every challenge to identify a lead candidate with all the characteristics we were looking for.

Yeah, Jim, so we ran across challenges at basically every step of the drug discovery pathway with this molecule, just starting with the availability of reagents to study it.

From the very beginning, we quickly realized that anything available commercially for PLA2G2D doesn't really quite work because all of these proteins that you can buy off the shelf are mostly expressed in prokaryotes.

And as you know, proteins expressed in bacteria aren't properly folded.

This is a protein that has multiple disulfide bonds.

And if it's not folded properly, it doesn't have its proper conformation.

It has no enzymatic activity.

And so for people that have cancer, what are you anticipating the positive effects will be for them?